Abstract
Immunogenicity is a major limitation to therapy with certain monoclonal antibodies and proteins. A major driver for immunogenicity is the presence of human T-cell epitopes within the protein sequence which can activate helper T-cells resulting in the sustained production of antibodies and neutralization of the therapeutic effect. Deimmunization is a new technology for location and removal of T-cell epitopes through the combined use of immunological and molecular biology techniques. In the case of deimmunization of antibodies, mutations to remove T-cell epitopes can generally be introduced without significantly reducing the binding affinity of the antibody. Typically, “deimmunized” antibodies are created with human constant regions and by expression of genes encoding these antibodies in mammalian cells. This chapter details a method for creation of a deimmunized antibody for production in mammalian cells.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Morrison, S.L. (1985) Transfectomas provide novel chimeric antibodies. Science, 229, 1202–1207.
Riechmann, L., Clark, M., Waldmann, H., and Winter, G. (1988) Reshaping human antibodies for therapy. Nature, 332, 323–327.
Baker, M.P., and Jones, T.D. (2007) Identification and removal of immunogenicity from therapeutic proteins. Curr. Opin. Drug Discov. Devel., 10, 219.
Chester, K.A., Baker, M.P., and Mayer, A. (2005) Overcoming the immunologic response to foreign enzymes in cancer therapy. Expert Rev. Clin. Immunol., 1, 549.
Amin, T., and Carter, G. (Nov. 2004) Immunogenicity issues with therapeutic proteins. Curr. Drug Discov., 12, 20–24.
Jones, T.D., Hanlon, M., Smith, B.J., Heise, C.T., Nayee, P.D., Sanders, D.A., Hamilton, A., Sweet, C., Unitt, E., Alexander, G., Lo, K.M., Gillies, S.D., Carr, F.J., and Baker, M.P. (2004) The development of a modified human IFN-alpha2b linked to the Fc portion of human IgG1 as a novel potential therapeutic for the treatment of hepatitis C virus infection. J. Interferon Cytokine Res., 24, 560–572.
Jones, T.D., Phillips, W.J., Smith, B.J., Bamford, C.A., Nayee, P.D., Baglin, T.P., Gaston, J.S.H., and Baker, M.P. (2005) Identification and removal of a promiscuous CD4+ T cell epitope from the C1 domain of factor VIII. J. Thromb. Haemost., 3, 1–10.
De Groot, A.S., Goldberg, M., Moise, L., and Martin, W. (2006) Evolutionary deimmunization: an ancillary mechanism for self-tolerance? Cell. Immunol., 244, 148–153.
Orlandi, R., Güssow, D.H., Jones, P.T., Winter, G. (1989) Cloning immunoglobulin variable domains for expression by the polymerase chain reaction. PNAS, 86, 3833–3837.
Acknowledgments
The authors would like to thank Dr Laura Perry and Dr Simon Keen for technical and editorial assistance in the development of the methods described.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Humana Press, a part of Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Jones, T.D., Crompton, L.J., Carr, F.J., Baker, M.P. (2009). Deimmunization of Monoclonal Antibodies. In: Dimitrov, A. (eds) Therapeutic Antibodies. Methods in Molecular Biology™, vol 525. Humana Press. https://doi.org/10.1007/978-1-59745-554-1_21
Download citation
DOI: https://doi.org/10.1007/978-1-59745-554-1_21
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-934115-92-3
Online ISBN: 978-1-59745-554-1
eBook Packages: Springer Protocols